Announcing a new article publication for Cardiovascular Innovations and Applications journal.

Transcatheter aortic valve replacement (TAVR) is currently a widely used option for patients with severe symptomatic aortic stenosis with high to low surgical risk. However, aortic regurgitation (AR) remains an “off-label” indication for TAVR, particularly for patients with mild or absent leaflet calcification or aortic annulus dimensions beyond the size of the bioprosthesis, which increase the risk of dislocation. With advances in transcatheter heart valve devices, the safety and efficacy of TAVR in treating patients with severe pure native AR has gained acceptance.
This article examines current evidence and clinical practice, and presents technological advancements in devices for AR.
CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.
Ran Liu, Zhaolin Fu and Jing Yao et al. Transcatheter Aortic Valve Replacement for Aortic Regurgitation – A Review. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0033